Consensus Chemed Corporation

Stocks

CHE

US16359R1032

Healthcare Facilities & Services

Market Closed - NYSE 00:00:03 13/08/2026 +04			5-day change	1st Jan Change
541.02 ^USD	+0.72%		-1.00%	+26.45%

08-06	Chemed Raises Quarterly Dividend to $0.70 a Share, Payable Sept. 3 to Shareholders of Record Aug. 17	MT
08-06	Chemed Corporation Declares Quarterly Dividend, Payable on September 3, 2026	CI

Evolution of the Average Target: Chemed Corporation

Evolution of the Target Price: Chemed Corporation

Changes in Analyst Recommendations: Chemed Corporation

d553ba21.56zcEYPWtnIEAQyQJ7TKHa7wfeeu_ylJCD2XYoK5Uuw.kfuKYc6shRNVeDvjSNGLR_-5SoTCtU8bPH74I8DyPYOQw7B_856DQlBUWQ~014933baacbfaf67b7a6822448b550a8

Analysts' recommendations: Chemed Corporation

07-31	Oppenheimer Adjusts Price Target on Chemed to $590 From $500, Maintains Outperform Rating	MT
07-30	RBC Raises Price Target on Chemed to $548 From $436, Keeps Sector Perform Rating	MT
07-30	The Fed Gets a Better Inflation Number
07-30	Analysts recommendations: Humana, Lam Research, Procter & Gamble, Carvana, Fair Isaac…
04-27	Chemed' VITAS Continues to Build Momentum, RBC Says	MT
04-27	RBC Lifts Price Target on Chemed to $436 From $422, Keeps Sector Perform Rating	MT
03-31	Chemed Can Unlock Value From Roto-Rooter Unit, Oppenheimer Says	MT
02-27	Chemed's Roto-Rooter Unit Faces Cost Pressures as Hospice Segment Looks Bullish, RBC Says	MT
02-27	Oppenheimer Adjusts Price Target on Chemed to $500 From $580, Maintains Outperform Rating	MT
02-27	RBC Downgrades Chemed to Sector Perform From Outperform, Cuts Price Target to $422 From $572	MT
01-22	Jefferies Downgrades Chemed to Hold From Buy, Adjusts Price Target to $475 From $550	MT
01-22	Analyst recommendations: Datadog, Albemarle, Halliburton, Netflix…
11-10	RBC Lowers Price Target on Chemed to $572 From $589, Keeps Outperform Rating	MT
11-04	Analysts recommendations: Apple, Comcast, Crocs, Eli Lilly, Palantir…
02/09/25	Analysts recommendations: Acuity, Block, Elf Beauty, Fortinet, Nvidia…
02/09/25	Jefferies Upgrades Chemed to Buy From Hold, Adjusts Price Target to $550 From $490	MT
31/07/25	RBC Lowers Price Target on Chemed to $589 From $640, Keeps Outperform Rating	MT
25/07/25	Jefferies Initiates Chemed at Hold With $500 Price Target	MT
30/06/25	RBC Cuts Price Target on Chemed to $640 From $674, Keeps Outperform Rating	MT
28/04/25	RBC Lifts Price Target on Chemed to $674 From $667, Keeps Outperform Rating	MT
14/03/25	RBC Raises Price Target on Chemed to $667 From $633, Keeps Outperform Rating	MT
21/05/24	RBC Cuts Price Target on Chemed to $697 From $712, Maintains Outperform Rating	MT
26/04/24	Chemed Reports 'Soft' Q1 as Roto-Rooter Continues to Face Pressure, Oppenheimer Says	MT
04/03/24	RBC Boosts Price Target on Chemed to $712 From $604, Expects 'Strong' VITAS Momentum to Continue in 2024; Outperform Kept	MT
29/02/24	Oppenheimer Raises Chemed Price Target to $650 From $625, Maintains Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CHEMED CORPORATION					+2.03%
	CVS HEALTH CORPORATION					+22.55%
	HCA HEALTHCARE, INC.					+9.64%
	FRESENIUS SE & CO. KGAA					+18.72%
	QUEST DIAGNOSTICS INCORPORATED					+3.41%
	DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY					+15.21%
	TENET HEALTHCARE CORPORATION					+5.7%
	REDE D'OR SÃO LUIZ S.A.					+45.25%
	FRESENIUS MEDICAL CARE AG					+4.37%
	DAVITA INC.					+20.35%
	Average					+14.72%
	Weighted average by Cap.					+15.85%